Clinical impact of time to positivity for Candida species on mortality in patients with candidaemia.
暂无分享,去创建一个
J. Sohn | Y. Yoon | M. J. Kim | Si-Hyun Kim
[1] H. Choi,et al. Antifungal Susceptibility to Amphotericin B, Fluconazole, Voriconazole, and Flucytosine in Candida Bloodstream Isolates from 15 Tertiary Hospitals in Korea , 2012, Annals of laboratory medicine.
[2] P. Martín-Dávila,et al. Emerging trends in candidemia: a higher incidence but a similar outcome. , 2012, The Journal of infection.
[3] M. Kim,et al. Risk factors for and clinical implications of mixed Candida/bacterial bloodstream infections , 2012, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[4] P. Hsueh,et al. Time to positivity of blood cultures of different Candida species causing fungaemia. , 2012, Journal of medical microbiology.
[5] J. Layden,et al. Timing of susceptibility-based antifungal drug administration in patients with Candida bloodstream infection: correlation with outcomes. , 2012, The Journal of antimicrobial chemotherapy.
[6] E. García-Cabrera,et al. Time to positivity of blood culture association with clinical presentation, prognosis and ESBL-production in Escherichia coli bacteremia , 2012, European Journal of Clinical Microbiology & Infectious Diseases.
[7] K. Laupland,et al. Time to blood culture positivity in Staphylococcus aureus bacteremia: association with 30-day mortality. , 2010, The Journal of infection.
[8] C. Liao,et al. Correlation between time to positivity of blood cultures with clinical presentation and outcomes in patients with Klebsiella pneumoniae bacteraemia: prospective cohort study. , 2009, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[9] S. Seo,et al. Effect of Antifungal Therapy Timing on Mortality in Cancer Patients with Candidemia , 2009, Antimicrobial Agents and Chemotherapy.
[10] G. Patel,et al. The Effect of Time to Antifungal Therapy on Mortality in Candidemia Associated Septic Shock , 2009, American journal of therapeutics.
[11] E. Anaissie,et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[12] J. Sobel,et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] J. Rhee,et al. SCORING SYSTEMS FOR PREDICTION OF MORTALITY IN PATIENTS WITH INTENSIVE CARE UNIT-ACQUIRED SEPSIS: A COMPARISON OF THE PITT BACTEREMIA SCORE AND THE ACUTE PHYSIOLOGY AND CHRONIC HEALTH EVALUATION II SCORING SYSTEMS , 2009, Shock.
[14] R. Ben-Ami,et al. Time to Blood Culture Positivity as a Marker for Catheter-Related Candidemia , 2008, Journal of Clinical Microbiology.
[15] M. Pfaller,et al. Therapy and outcome of Candida glabrata versus Candida albicans bloodstream infection. , 2008, Diagnostic microbiology and infectious disease.
[16] I. de Benito,et al. Time-to-positivity in patients with Escherichia coli bacteraemia. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[17] K. Laupland,et al. Adequacy of empirical antifungal therapy and effect on outcome among patients with invasive Candida species infections. , 2007, The Journal of antimicrobial chemotherapy.
[18] S. Fridkin,et al. Impact of early central venous catheter removal on outcome in patients with candidaemia. , 2007, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.
[19] K. Garey,et al. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[20] G. Peralta,et al. Time to positivity in blood cultures of adults with Streptococcus pneumoniae bacteremia , 2006, BMC infectious diseases.
[21] B. A. Forbes,et al. Time to Blood Culture Positivity as a Predictor of Clinical Outcome of Staphylococcus aureus Bloodstream Infection , 2006, Journal of Clinical Microbiology.
[22] Victoria J. Fraser,et al. Delaying the Empiric Treatment of Candida Bloodstream Infection until Positive Blood Culture Results Are Obtained: a Potential Risk Factor for Hospital Mortality , 2005, Antimicrobial Agents and Chemotherapy.
[23] D. Hospenthal,et al. Effect of Inoculum Size on Detection of Candida Growth by the BACTEC 9240 Automated Blood Culture System Using Aerobic and Anaerobic Media , 2005, Journal of Clinical Microbiology.
[24] L. Rubin,et al. Initial Concentration of Staphylococcus epidermidis in Simulated Pediatric Blood Cultures Correlates with Time to Positive Results with the Automated, Continuously Monitored BACTEC Blood Culture System , 2002, Journal of Clinical Microbiology.
[25] J. Vincent,et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.
[26] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.
[27] B. Yangco,et al. CDC definitions for nosocomial infections. , 1989, American journal of infection control.
[28] J M Hughes,et al. CDC definitions for nosocomial infections, 1988. , 1988, American journal of infection control.
[29] P. Della‐Latta,et al. The impact of delaying the initiation of appropriate antifungal treatment for Candida bloodstream infection. , 2010, Medical mycology.
[30] Li Guanghu,et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection:2009 update by the Infectious Diseases Society of America , 2010 .
[31] W. Knaus,et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. 1992. , 2009, Chest.
[32] Steven D. Brown,et al. Reference method for broth dilution antifungal susceptibility testing of yeasts : Third informational supplement , 2008 .
[33] C. Mackenzie,et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. , 1987, Journal of chronic diseases.